Cytokines in hematopoietic cell transplantation and related cellular therapies

IF 2.2 4区医学 Q3 HEMATOLOGY

Best Practice & Research Clinical Haematology Pub Date : 2024-12-01 DOI:10.1016/j.beha.2025.101600

Abdul-Hamid Bazarbachi , Markus Y. Mapara

{"title":"Cytokines in hematopoietic cell transplantation and related cellular therapies","authors":"Abdul-Hamid Bazarbachi , Markus Y. Mapara","doi":"10.1016/j.beha.2025.101600","DOIUrl":null,"url":null,"abstract":"<div><div>Cytokines are pleiotropic molecules involved in hematopoiesis, immune responses, infections, and inflammation. They play critical roles in hematopoietic cell transplantation (HCT) and immune effector cell (IEC) therapies, mediating both therapeutic and adverse effects. Thus, cytokines contribute to the immunopathology of graft-<em>versus</em>-host disease (GVHD), cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). This review examines cytokine functions in these contexts, their influence on engraftment and immune recovery post-transplantation, and their role in mediating toxicities. We focus on current and potential uses of cytokines to enhance engraftment and potentiate IEC therapies, as well as strategies to mitigate cytokine-mediated complications using cytokine blockers (<em>e.g</em>., tocilizumab, anakinra) and JAK inhibitors (<em>e.g</em>., ruxolitinib). We discuss new insights into GVHD physiology that have led to novel treatments, such as CSF1R blockade, which is effective in refractory chronic GVHD.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 4","pages":"Article 101600"},"PeriodicalIF":2.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research Clinical Haematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521692625000052","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Cytokines are pleiotropic molecules involved in hematopoiesis, immune responses, infections, and inflammation. They play critical roles in hematopoietic cell transplantation (HCT) and immune effector cell (IEC) therapies, mediating both therapeutic and adverse effects. Thus, cytokines contribute to the immunopathology of graft-versus-host disease (GVHD), cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). This review examines cytokine functions in these contexts, their influence on engraftment and immune recovery post-transplantation, and their role in mediating toxicities. We focus on current and potential uses of cytokines to enhance engraftment and potentiate IEC therapies, as well as strategies to mitigate cytokine-mediated complications using cytokine blockers (e.g., tocilizumab, anakinra) and JAK inhibitors (e.g., ruxolitinib). We discuss new insights into GVHD physiology that have led to novel treatments, such as CSF1R blockade, which is effective in refractory chronic GVHD.

查看原文本刊更多论文

细胞因子在造血细胞移植及相关细胞治疗中的作用

细胞因子是参与造血、免疫反应、感染和炎症的多效分子。它们在造血细胞移植（HCT）和免疫效应细胞（IEC）治疗中发挥关键作用，介导治疗和不良反应。因此，细胞因子有助于移植物抗宿主病（GVHD）、细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）的免疫病理。本文综述了细胞因子在这些情况下的功能，它们对移植和移植后免疫恢复的影响，以及它们在介导毒性中的作用。我们专注于细胞因子的当前和潜在应用，以增强植入和增强IEC治疗，以及使用细胞因子阻滞剂（例如，tocilizumab, anakinra）和JAK抑制剂（例如，ruxolitinib）减轻细胞因子介导的并发症的策略。我们讨论了关于GVHD生理学的新见解，这些新见解导致了新的治疗方法，例如CSF1R阻断，它对难治性慢性GVHD有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Best Practice & Research Clinical Haematology 医学-血液学

CiteScore

4.20

自引率

0.00%

发文量

审稿时长

35 days

期刊介绍： Best Practice & Research Clinical Haematology publishes review articles integrating the results from the latest original research articles into practical, evidence-based review articles. These articles seek to address the key clinical issues of diagnosis, treatment and patient management. Each issue follows a problem-orientated approach which focuses on the key questions to be addressed, clearly defining what is known and not known, covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the Editor welcomes suggestions from potential authors.